Baillie Leslie W
Welsh School of Pharmacy, Cardiff University, Wales, UK.
Hum Vaccin. 2009 Dec;5(12):806-16. doi: 10.4161/hv.9777. Epub 2009 Dec 9.
Anthrax is caused by a Gram-positive aerobic spore-forming bacillus called Bacillus anthracis. Although primarily a disease of animals, it can also infect man, sometimes with fatal consequences. As a result of concerns over the illicit use of this organism, considerable effort is focused on the development of therapies capable of conferring protection against anthrax. while effective concerns over the toxicity of the current vaccines have driven the development of second-generation products. Recombinant Protective Antigen (rPA), the nontoxic cell-binding component of anthrax lethal toxin, is the principal immunogen of the vaccines currently undergoing human clinical trials. While these new vaccines are likely to show reduced side effects they will still require multiple needle based dosing and the inclusion of the adjuvant alum which will make them expensive to administer and stockpile. To address these issues, researchers are seeking to develop vaccine formulations capable of stimulating rapid protection following needle-free injection which are stable at room temperature to facilitate stockpiling and mass vaccination programs. Recent concerns over the potential use of molecular biology to engineer vaccine resistant strains has prompted investigators to identify additional vaccine targets with which to extend the spectrum of protection conferred by rPA. While the injection of research dollars has seen a dramatic expansion of the anthrax vaccine field it is sobering to remember that work to develop the current second generation vaccines began around the time of the first gulf war. Almost two decades and millions of dollars later we still do not have a replacement vaccine and even when we do some argue that the spectrum of protection that it confers will not be as broad as the vaccine it replaces. If we are to respond effectively to emerging biological threats we need to develop processes that generate protective vaccines in a meaningful time frame and yield products in months not decades!
炭疽病由一种革兰氏阳性需氧芽孢杆菌——炭疽芽孢杆菌引起。虽然它主要是一种动物疾病,但也能感染人类,有时会导致致命后果。由于担心这种生物体被非法使用,人们投入了大量精力来研发能够提供炭疽防护的疗法。同时,对现有疫苗毒性的担忧促使了第二代产品的研发。重组保护性抗原(rPA)是炭疽致死毒素的无毒细胞结合成分,是目前正在进行人体临床试验的疫苗的主要免疫原。虽然这些新疫苗可能副作用较小,但仍需要多次注射给药,并且含有佐剂明矾,这将使其给药和储存成本高昂。为了解决这些问题,研究人员正在寻求开发能够在无针注射后迅速提供保护的疫苗制剂,这些制剂在室温下稳定,便于储存和大规模疫苗接种计划。最近对利用分子生物学制造抗疫苗菌株的潜在用途的担忧促使研究人员确定额外的疫苗靶点,以扩大rPA所提供的保护范围。虽然投入的研究资金使炭疽疫苗领域有了显著扩展,但值得清醒认识的是,当前第二代疫苗的研发工作始于第一次海湾战争时期。近二十年后,花费了数百万美元,我们仍然没有替代疫苗,甚至即便有了,一些人认为它所提供的保护范围也不如被替代的疫苗广泛。如果我们要有效应对新出现的生物威胁,就需要开发能够在有意义的时间框架内生产出保护性疫苗的流程,并在数月而非数十年内产出产品!